Can Dupixent Cause Lymphoma? Latest Research in 2025

Dupixent Side Effects: Latest Research on Cancer and Lymphoma Risk 2025

Dupixent, used by over 600,000 patients worldwide for treating conditions like atopic dermatitis and asthma, has raised important questions about potential Dupixent side effects cancer risks. As this breakthrough medication continues to transform treatment approaches, patients and healthcare providers alike seek clarity on its long-term safety profile.

“Anyone who took Dupixent deserves to know the full picture. If you’ve suffered serious illness without being properly warned about potential risks like CTCL, you deserve justice — and we will fight to ensure your voice is heard and your harms are compensated.” By Attorney Martin Schmidt

Recent research and safety monitoring between 2024-2025 have provided new insights into the relationship between Dupixent and potential cancer risks, specifically lymphoma.

This comprehensive review examines the latest scientific evidence, clinical studies, and regulatory updates to address these crucial safety concerns.

Throughout this article, we will explore the current understanding of Dupixent’s safety profile, analyze lymphoma risk data, evaluate broader cancer risks, and discuss essential monitoring protocols for patients. We will also provide practical risk management strategies to help inform treatment decisions.

Understanding Dupixent’s Safety Profile

Clinical studies have established a well-documented safety profile for Dupixent across multiple conditions. The medication’s safety assessment encompasses extensive monitoring of adverse reactions and long-term effects.

Overview of Known Side Effects

The most frequent adverse reactions vary by condition. In atopic dermatitis patients, injection site reactions and eye-related complications occur most commonly ¹. Furthermore, clinical data shows that patients experienced injection site reactions (up to 38%) and conjunctivitis (up to 21%) as primary side effects ¹.

Common adverse events across conditions include:

• Viral infections and headaches
• Nasopharyngitis and back pain
• Diarrhea and arthralgia
• Urinary tract infections
• Local administration reactions ²

Regulatory Safety Updates 2024-2025

Recent safety monitoring during 2024-2025 has validated Dupixent’s established safety profile. Safety results from the LIBERTY-CUPID phase 3 studies remained consistent with previously known patterns ¹. Moreover, pooled data from BOREAS and NOTUS trials revealed that while most side effects were mild, cholecystitis occurred in 0.6% of Dupixent patients compared to 0.1% on placebo ².

Risk Assessment Framework

The risk assessment protocol primarily focuses on monitoring several key areas. Healthcare providers actively track potential allergic reactions, which though rare in studies, can range from mild rashes to severe responses requiring immediate medical attention ¹. Additionally, the framework includes systematic evaluation of eosinophilic conditions, particularly in asthma patients ³.

Ongoing safety assessments concentrate on ocular complications, with healthcare providers recommended to conduct ophthalmological examinations for patients developing persistent conjunctivitis or signs of keratitis ¹. The current risk management strategy encompasses regular monitoring of blood eosinophil levels and careful observation for any signs of vasculitis or inflammatory conditions ².

Lymphoma Risk: Current Evidence

Recent research has revealed significant findings regarding lymphoma risk associated with Dupixent treatment. Multiple clinical studies have documented cases requiring careful medical attention and monitoring.

Clinical Study Findings

A comprehensive analysis identified 55 cases of cutaneous T-cell lymphoma (CTCL) in Dupixent-treated patients ². The majority of these cases, specifically 45 cases (81%), were diagnosed as mycosis fungoides ². Notably, 61.2% of CTCL diagnoses occurred within the first year of starting Dupixent treatment ².

Case Report Analysis

A detailed case series examination revealed distinctive patterns in patient responses. Among 14 patients suspected of CTCL during Dupixent treatment, 11 developed a specific lymphoid reaction with unique characteristics ¹. These reactions manifested approximately 4 months after treatment initiation ¹.

Key clinical manifestations included:

• Burning sensation and intensified itching
• Maculopapular exanthema
• Lichenification in lower trunk regions
• Distinctive histopathologic features

Statistical Risk Assessment

Statistical analysis demonstrates substantial risk variations across different age groups. Patients over 60 years showed a 0.725% risk of developing CTCL ². In contrast, patients under 40 years exhibited a lower risk at 0.109% ². The overall relative risk of developing CTCL in Dupixent-treated patients was 4.59 times higher than untreated individuals ².

A matched cohort study of 25 patients diagnosed with mycosis fungoides following Dupixent exposure reported comparable outcomes to non-exposed patients ³. The two-year overall survival rate for Dupixent-exposed patients reached 100%, whereas progression-free survival stood at 41.5% ³.

Several biological mechanisms have been proposed for these observations. Scientists theorize that Dupixent might influence the progression of initially benign lymphoid infiltrates, potentially leading to T-lymphocyte clonal expansion ¹. Subsequently, this could result in malignant transformation in certain cases, although the exact pathomechanism remains under investigation ¹.

Cancer Risk Beyond Lymphoma

Research examining Dupixent’s broader cancer implications has yielded significant insights beyond lymphoma-related concerns. A comprehensive analysis of medical records from 90 patients revealed diverse cancer manifestations requiring careful consideration ¹.

Systematic Review of Cancer Cases

A thorough examination identified three patients who developed aggressive cancers after Dupixent treatment, including glioblastoma multiforme, fatal pancreatic cancer, and advanced sinonasal cancer ¹. Indeed, multiple case reports documented various malignancies:

• Solid tumors including sinonasal, pancreatic, lung, testicular, and prostate cancers ¹
• Three cases of testicular tumors, embryonic cancer, and bladder cancer post-treatment ¹
• Sporadic occurrences of serious malignancies in multicenter studies ¹

Biological Mechanisms

The molecular pathway through which Dupixent might influence cancer development centers on IL-4 and IL-13 signaling. Consequently, Dupilumab, an IgG4-monoclonal antibody, binds to IL-4 receptor alpha, blocking downstream IL-4 and IL-13 signaling via JAK-STAT ¹.

IgG4 expression appears elevated in various tumor tissues, including pancreatic and gastric cancers ¹. Nevertheless, recent systematic reviews indicate no increased risk of malignancy when specifically targeting IL-13 and IL-4 ². The medication might even offer potential benefits by downregulating PD-1 expression on tumor-infiltrating lymphocytes, potentially enhancing cancer immunotherapy ².

Population-Based Studies

Analysis of 3,260 dupilumab-exposed and 45,143 unexposed person-years revealed 721 primary malignancies ³. The findings showed:

• 42 cases among exposed patients (incident rate = 12.88) ³
• 679 cases in unexposed patients (incident rate = 15.04) ³
• Keratinocyte cancers occurred in 26 exposed patients (IR = 7.98) compared to 451 unexposed patients (IR = 9.99) ³

A recent population-based cohort study reported reduced incidence of certain solid tumors, such as breast cancer ². Between January 2017 and the fourth quarter of 2023, FAERS documented 181,575 unique reports of dupilumab-related adverse events, with 606 cases involving neoplasms ⁴.

Current evidence suggests Dupixent remains safe for most patients with cancer ¹. The medication shows no significant negative effects on most tumors, except for certain lymphomas ¹. Registry data supports these findings, showing no increased risk of malignancy in long-term monitoring ².

Patient Monitoring Protocols

Proper monitoring remains essential for patients receiving Dupixent treatment, requiring systematic observation and regular medical assessment. Physicians must implement structured protocols to track potential side effects and ensure patient safety.

Early Warning Signs

Medical professionals emphasize vigilant monitoring for specific symptoms that warrant immediate attention. Patients should watch for signs of allergic reactions, primarily breathing problems, swelling of face or throat, fainting, dizziness, or fever ¹. Accordingly, any new or worsening joint symptoms require prompt medical evaluation, as some patients experienced mobility issues severe enough to need hospitalization ¹.

Critical symptoms requiring immediate medical attention include:

• Chest pain or worsening shortness of breath
• Persistent fever or unusual fatigue
• Rash development or skin changes
• Eye-related complications, especially blurred vision
• Numbness or tingling in extremities ¹

Screening Recommendations

Current protocols advocate for comprehensive screening before and during treatment. Blood tests remain the cornerstone of monitoring, with 91% of patients receiving screening laboratory tests ⁴. Essential screening components include:

Full blood count analysis, liver function tests, and kidney function assessment form the foundation of laboratory monitoring ⁴. Certainly, these tests help identify potential complications early, though 93% of observed laboratory abnormalities classify as mild ⁴.

For patients with pre-existing conditions, specialized screening might be necessary. Essentially, those with asthma require periodic evaluation to ensure continued effectiveness of their usual asthma treatment ⁵. Furthermore, patients on medications like warfarin need careful monitoring due to potential interactions ⁵.

Follow-up Schedule

Regular check-ups form the backbone of patient monitoring, with healthcare providers establishing individualized follow-up schedules. The average monitoring period extends to 255 days, primarily involving three sets of blood tests per patient ⁴.

Routine follow-up appointments serve multiple purposes:

• Assessment of treatment response
• Monitoring of potential side effects
• Adjustment of treatment plans when necessary
• Documentation of progress for insurance purposes ⁶

For long-term Dupixent therapy, healthcare providers typically schedule periodic physical exams and may order imaging studies based on individual risk factors ⁷. Hence, maintaining detailed records of any new symptoms or changes becomes crucial for effective monitoring ⁷.

Risk Management Strategies

Managing potential cancer risks associated with Dupixent treatment requires a structured approach combining preventive strategies, treatment alternatives, and collaborative decision-making between healthcare providers and patients.

Preventive Measures

Effective risk management primarily focuses on careful patient selection and continuous monitoring. Healthcare providers must evaluate each patient’s medical history, primarily those with previous cancer diagnoses ². Rather than excluding all patients with cancer history, physicians now assess cases individually, as data shows six patients completed one year of Dupixent treatment without cancer progression or recurrence ².

Current preventive protocols emphasize three main pillars:

• Identifying and avoiding trigger factors
• Addressing skin barrier dysfunction
• Implementing targeted anti-inflammatory therapy ⁸

Significantly, long-term safety data indicates Dupixent therapy does not connect to higher malignancy risk ³. Still, clinicians must exercise caution and consider treatment decisions case-by-case, simultaneously consulting with oncologists when necessary ³.

Alternative Treatment Options

For patients seeking alternatives to Dupixent, several FDA-approved medications offer viable options. Adbry, Cibinqo, Eucrisa, Opzelura, and Rinvoq have emerged as potential alternatives ⁷. These medications might be more suitable for certain individuals based on their unique mechanisms of action and side effect profiles.

Traditional treatment approaches include:

• Topical corticosteroids, which remain the primary treatment for mild cases
• Systemic immunosuppressants for moderate-to-severe cases
• Phototherapy, soon becoming a consideration for specific patient groups ⁴

Regardless of the chosen alternative, healthcare providers must carefully weigh each option’s benefits and risks. Systemic immunosuppressants, while effective, often require regular blood monitoring and may cause substantial side effects ¹.

Shared Decision Making

The foundation of effective risk management lies in collaborative decision-making between healthcare providers and patients. A specialist, typically a dermatologist, initiates Dupixent prescriptions in hospital or community clinical settings ¹. In areas with limited access to dermatologists, general pediatricians, allergists, or immunologists with specific training may prescribe the medication.

Key considerations for shared decision-making include:

1. Insurance coverage and medication costs
2. Patient’s medical history and current health status
3. Previous treatment responses
4. Long-term treatment goals ⁷

Before switching medications, patients should contact their insurance providers to understand coverage options and discuss potential alternatives with their healthcare providers ⁷. Treatment decisions factor in the patient’s specific condition, severity, and personal preferences.

For optimal outcomes, healthcare providers must carefully evaluate each case, considering both immediate and long-term implications. The ultimate goal remains achieving remission with minimal drug toxicity while improving the patient’s quality of life ³. This approach ensures patients receive appropriate care while maintaining vigilant monitoring for potential side effects.

Conclusion

Research between 2024-2025 provides substantial evidence regarding Dupixent’s safety profile and cancer risks. Clinical data demonstrates that while lymphoma cases require attention, particularly CTCL with a 4.59 times higher relative risk, overall cancer occurrence remains comparable to untreated populations.

Population-based studies spanning 3,260 Dupixent-exposed patients actually showed lower incident rates of primary malignancies (12.88) compared to unexposed groups (15.04). Therefore, current evidence supports Dupixent’s safety for most patients, though specific monitoring remains essential.

Healthcare providers should maintain vigilant screening protocols, especially during the first year of treatment when 61.2% of CTCL diagnoses occur. Regular blood tests, physical examinations, and careful documentation of symptoms form the cornerstone of effective patient monitoring.

Success in managing potential risks depends on three key factors: thorough preventive measures, appropriate alternative treatment consideration when needed, and strong collaboration between healthcare providers and patients. Through careful individual assessment and structured monitoring, medical teams can help ensure optimal outcomes while minimizing potential risks.

As scientific understanding continues advancing, healthcare providers gain better tools for making informed treatment decisions. This growing knowledge base helps create more effective, personalized approaches for patients requiring long-term Dupixent therapy.

References

[1] – https://www.ncbi.nlm.nih.gov/books/NBK598238/
[2] – https://pmc.ncbi.nlm.nih.gov/articles/PMC10412017/
[3] – https://pmc.ncbi.nlm.nih.gov/articles/PMC9918040/
[4] – https://pmc.ncbi.nlm.nih.gov/articles/PMC5752457/
[5] – https://www.ncbi.nlm.nih.gov/books/NBK585114/
[6] – https://www.dupixenthcp.com/patient-support/dupixent-myway
[7] – https://www.singlecare.com/blog/dupixent-alternatives/
[8] – https://pmc.ncbi.nlm.nih.gov/articles/PMC10164714/

Learn more about the Dupixent Lawsuit here.

Post: Can Dupixent Cause Lymphoma? Updated on September 19, 2025